Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

[1]  Zhihua Zheng,et al.  Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients , 2020, Cell Host & Microbe.

[2]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[3]  C. Hunter,et al.  Cytokine Storms: Understanding COVID-19 , 2020, Immunity.

[4]  Zhenyu Li,et al.  The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019 , 2020, EMBO molecular medicine.

[5]  M. Llorian,et al.  Type I and III interferons disrupt lung epithelial repair during recovery from viral infection , 2020, Science.

[6]  F. Granucci,et al.  Type III interferons disrupt the lung epithelial barrier upon viral recognition , 2020, Science.

[7]  Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) , 2020, Chinese medical journal.

[8]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[9]  T. Liang,et al.  Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study , 2020, BMJ.

[10]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[11]  Malik Peiris,et al.  Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.

[12]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[13]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[14]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[15]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[16]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[17]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  Qin Ning,et al.  Clinical and immunological features of severe and moderate coronavirus disease 2019 , 2020 .

[19]  R. Baric,et al.  Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during MERS Coronavirus Infection , 2019, mBio.

[20]  E. Andreakos,et al.  Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control , 2018, Current Opinion in Immunology.

[21]  Bernstein,et al.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza a , 2018 .

[22]  S. Kotenko,et al.  Interferon‐&lgr; Mediates Non‐redundant Front‐Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness , 2017, Immunity.

[23]  K. Fitzgerald,et al.  Inflammasome Complexes: Emerging Mechanisms and Effector Functions , 2016, Cell.

[24]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[25]  E. Andreakos,et al.  Neutrophils in viral infections: Current concepts and caveats , 2015, Journal of leukocyte biology.

[26]  A. Sher,et al.  Type I interferons in infectious disease , 2015, Nature Reviews Immunology.

[27]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[28]  Sophia Davidson,et al.  Pathogenic potential of interferon αβ in acute influenza infection , 2014, Nature Communications.

[29]  E. Fish,et al.  The yin and yang of viruses and interferons , 2012, Trends in Immunology.

[30]  R. Brookmeyer,et al.  Incubation periods of acute respiratory viral infections: a systematic review , 2009, The Lancet Infectious Diseases.

[31]  J. Taubenberger,et al.  The pathology of influenza virus infections. , 2008, Annual review of pathology.

[32]  R. Baric,et al.  Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain , 2007, Journal of Virology.

[33]  P. Palese,et al.  Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists , 2006, Journal of Virology.

[34]  W. Lim,et al.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.

[35]  G. Sen,et al.  Viruses and interferons. , 2001, Annual review of microbiology.